Icon (NASDAQ:ICLR) Shares Sold Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Icon Plc (NASDAQ:ICLR). In a filing disclosed on September 01st, the Representative disclosed that they had sold between $15,001 and $50,000 in Icon stock on August 14th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Home Depot (NYSE:HD) on 8/24/2026.
• Sold $50,001 – $100,000 in shares of Procter & Gamble (NYSE:PG) on 8/24/2026.
• Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 8/24/2026.
• Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/21/2026.
• Sold $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 8/21/2026.
• Sold $15,001 – $50,000 in shares of Honeywell Aerospace (NASDAQ:HONA) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Colgate-Palmolive (NYSE:CL) on 8/19/2026.
• Sold $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 8/18/2026.

Icon Price Performance

NASDAQ ICLR opened at $163.58 on Friday. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91. The business’s fifty day moving average is $168.15 and its two-hundred day moving average is $135.31. The stock has a market capitalization of $12.53 billion, a P/E ratio of 38.40, a P/E/G ratio of 6.62 and a beta of 1.20. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.55 by $0.01. The business had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.The company’s revenue was up 2.3% compared to the same quarter last year. During the same period last year, the company posted $3.26 EPS. On average, research analysts forecast that Icon Plc will post 9.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Zacks Research upgraded Icon from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. Barclays raised their target price on shares of Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a report on Thursday, June 25th. Truist Financial restated a “buy” rating and set a $209.00 price target (up from $207.00) on shares of Icon in a report on Friday, July 31st. Bank of America raised their price objective on shares of Icon from $125.00 to $150.00 and gave the stock an “underperform” rating in a research note on Thursday, June 25th. Finally, Robert W. Baird set a $194.00 target price on shares of Icon in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $170.40.

Insider Activity

In other Icon news, Director Ronan Murphy sold 841 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total value of $138,167.89. Following the transaction, the director directly owned 3,847 shares of the company’s stock, valued at $632,023.63. This represents a 17.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Eugene Mccague sold 841 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total value of $138,167.89. Following the sale, the director directly owned 3,811 shares of the company’s stock, valued at $626,109.19. This trade represents a 18.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 9,531 shares of company stock valued at $1,565,764. 44.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. VELA Investment Management LLC lifted its position in Icon by 511.4% in the 2nd quarter. VELA Investment Management LLC now owns 12,192 shares of the medical research company’s stock worth $2,118,000 after buying an additional 10,198 shares in the last quarter. Concurrent Investment Advisors LLC acquired a new position in shares of Icon in the second quarter worth $6,337,000. Clifford Swan Investment Counsel LLC acquired a new position in shares of Icon in the second quarter worth $236,000. Maple Rock Capital Partners Inc. raised its holdings in shares of Icon by 257.8% during the second quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock worth $208,383,000 after acquiring an additional 864,300 shares in the last quarter. Finally, American Capital Management Inc. purchased a new stake in shares of Icon during the second quarter worth $490,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.